C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Group 1 - C4 Therapeutics, Inc. (CCCC) has experienced a significant decline of 26.2% over the past four weeks, but it is now in oversold territory, indicating a potential for a trend reversal [1] - The Relative Strength Index (RSI) for CCCC is at 17.81, suggesting that the heavy selling pressure may be exhausting, which could lead to a rebound in the stock price [5] - There is strong consensus among Wall Street analysts that CCCC will report better earnings than previously predicted, with a 0.3% increase in the consensus EPS estimate over the last 30 days [6] Group 2 - CCCC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7]